title: Current pipelines for neglected diseases.
abstract: This paper scrutinises pipelines for Neglected Diseases (NDs), through freely accessible and at-least-weekly updated trials databases. It updates to 2012 data provided by recent publications, and integrates these analyses with information on location of trials coordinators and patients recruitment status. Additionally, it provides (i) disease-specific information to better understand the rational of investments in NDs, (ii) yearly data, to understand the investment trends. The search identified 650 clinical studies. Leishmaniasis, Arbovirus infection, and Dengue are the top three diseases by number of clinical studies. Disease diffusion risk seems to be the most important driver of the clinical trials target choice, whereas the role played by disease prevalence and unmet need is controversial. Number of trials is stable between 2005 and 2010, with an increase in the last two years. Patient recruitment was completed for most studies (57.6%), and Phases II and III account for 35% and 28% of trials, respectively. The primary purpose of clinical investigations is prevention (49.3%), especially for infectious diseases with mosquitoes and sand flies as the vector, and treatment (43.2%), which is the primary target for parasitic diseases Research centres and public organisations are the most important clinical studies sponsors (58.9%), followed by the pharmaceutical industry (24.1%), foundations and non-governmental organisations (9.3%). Many coordinator centres are located in less affluent countries (43.7%), whereas OECD countries and BRICS account for 34.7% and 17.5% of trials, respectively. Information was partially missing for some parameters. Notwithstanding, and despite its descriptive nature, this research has enhanced the evidence of the literature on pipelines for NDs. Future contributions may further investigate whether trials metrics are consistent with the characteristics of the interested countries and the explicative variables of trials location, target (disease) choice, and the object of the trials.
authors.affiliation: Department of Pharmaceutical Sciences, Università del Piemonte Orientale, Novara, Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: di Procolo
authors.affiliation: Department of Pharmaceutical Sciences, Università del Piemonte Orientale, Novara, Italy; CERGAS (Centre for Research on Health and Social Care Management), Università Bocconi, Milano, Italy.
authors.forename: Claudio
authors.initials: C
authors.lastname: Jommi
mesh_terms: D035843:Biomedical Research / Q000639:trends; D002986:Clinical Trials as Topic; D016208:Databases, Factual; D004358:Drug Therapy / Q000639:trends; D006801:Humans; D058069:Neglected Diseases / Q000188:drug therapy* / Q000517:prevention & control*; D018579:Patient Selection; D011203:Poverty; D014612:Vaccines / Q000276:immunology*
chemical_list: D014612:Vaccines